The senior management currently consists of the Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer, Chief Operating Officer, Head of Research and CMC, Chief Medical Officer, General Counsel, Global Head of Corporate Communications, General Manager Europe and General Manager, US Business Unit.

Marty J Duvall, CEO

Marty J Duvall

Chief Executive Officer, CEO

Marty J Duvall was appointed as CEO in 2020.


Marty has extensive experience from executive leadership roles in drug development and commercialization within the global biotechnology and pharmaceutical industry, including a unique experience from the oncology and hematology sphere.


Prior to joining Oncopeptides Marty was Chief Executive Officer of Tocagen Inc. Previously he served as Executive Vice President, Chief Commercial Officer of ARIAD pharmaceuticals, and led the company’s transformation into a fully integrated, global biotechnology company. Marty has been Senior Vice President and General Manager, oncology, at Merck & Co., Inc. Earlier he was Senior Vice President, global marketing and commercial operations at Abraxis Bioscience, Inc. and Senior Vice President, commercial operations, for MGI Pharma. He has held several commercialization, marketing and sales roles in oncology at Sanofi.


Marty holds a MA in chemistry from Johns Hopkins University, an MBA from the University of Kansas, and a BS in chemistry from Muhlenberg College.


Born: 1962
Holdings in Oncopeptides: 8,800 shares and 406,262 options**.
Other Current positions: Chairman of Oncopeptides, Inc. and Board member of Oncopeptides Incentive AB.

Anders Martin-Löf

Anders Martin-Löf, MSc

Chief Financial Officer, CFO, and Deputy CEO

Anders Martin-Löf was appointed CFO in 2018 and is responsible for Finance, HR, IT & Administration. He is also the Deputy CEO of Oncopeptides AB since 2020.


Anders was previously CFO of Wilson Therapeutics AB and RaySearch Laboratories AB, both listed on Nasdaq Stockholm. He held various business development positions for Swedish Orphan Biovitrum where he also served as Director of Investor Relations. In addition, he has worked as a management consultant at the Boston Consulting Group, Cell Network and as co-founder and CEO of ScienceCap.


Anders holds an MSc in Engineering Physics from the Royal Institute of Technology, and a BA in Business Administration and Economics, from Stockholm University.


Born: 1971
Holdings in Oncopeptides: 10,000 shares and 274,376 options**.
Other current positions: Director of Cantargia AB and chairman of the board of Oncopeptides Incentive AB.

Andrea Passalacqua - General Manager, Europe

Andrea Passalacqua

General Manager, Europe

Andrea Passalacqua was appointed General Manager, Europe, in March 2021.


Andrea has extensive commercial experience within the biotech and pharmaceutical industry and significant therapeutic area expertise in the fields of hematology, oncology, inflammation and immunology.


Before joining Oncopeptides, Andrea was General Manager in Italy for Bluebird bio, where he led the preparation for a gene therapy launch in Italy. Previously, he served as Business Unit Director for Amgen Switzerland in the Inflammation and Immunology Unit. Earlier, he was Business Unit Director for Celgene Switzerland where he was responsible for the hematology, oncology and inflammation and immunology units.


During his 11-years tenure at Celgene he also held several leading international roles in different geographies including: Business Unit Director Spain, Executive Director Pricing and Market Access Europe, Senior Director Global Marketing Oncology, and Director European Oncology Franchise. Prior to joining the biotech industry, Andrea was working as a consultant at McKinsey & Company.


Andrea holds an MBA from IESE Business School (University of Navarra, Spain) and a degree in Telecom Engineering from the University La Sapienza in Rome, Italy.


Born: 1977
Holdings in Oncopeptides: 5,000 shares and 50,000 options**.
Other Current positions: -

Eva Nordström

Eva Nordström, MSc Pharm

Chief Operating Officer, COO

Eva Nordström was appointed as Head of Clinical Development in 2012 and Chief Operating Officer 2020. Eva is responsible for strategic and operational deliveries in Biostatistics, Clinical Operations, Data Management, Global Drug Supply and Project & Process Management.


Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.


Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.


Born: 1970
Holdings in Oncopeptides: 120,200 shares and 156,407 options**.
Other current positions: Alternate Director of Utilica AB.

Fredrik Lehmann, Head of Research and CMC

Fredrik Lehmann, PhD

Head of Research and CMC (Chemistry, Manufacturing & Control)

Fredrik Lehmann was appointed Head of CMC in 2008 and Head of Research in 2018.


In addition to being Head of CMC for Oncopeptides, Fredrik is an independent consultant within preclinical research and CMC. Fredrik has previously held positions at several life sciences businesses including Pharmacia, Personal Chemistry, Biovitrum and Recipharm. He has also co-founded six life science companies.


Fredrik holds a PhD in medicinal chemistry from Gothenburg University.


Born: 1976
Holdings in Oncopeptides: 16,000 shares (15,000 directly owned, 1,000 indirectly owned through OT Pharmaceuticals AB), 13 employee options* and 106,705 options**.
Other current positions: Director and CEO of OT Pharmaceuticals AB. Chairman of the board of Synartro AB. Board member of Immuneed AB and Sprint Bioscience. Member of the Scientific Advisory Board at Akthelia Pharmaceuticals.

Jakob Lindberg

Jakob Lindberg, Med Lic

Chief Scientific Officer, CSO

Jakob Lindberg was appointed as CSO in 2020.


In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB.


Jakob was CEO of Oncopetides AB between 2011 and 2020. His previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.


Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.


Born: 1972
Holdings in Oncopeptides: 618,331 (603,031 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB) and 349,668 options**.
Other current positions: Director of Affibody Medical AB and Lindberg Life-Science AB. CEO of Lindberg Life-Science AB.

Karolina Vilval

Karolina Vilval, LL.M

General Counsel

Karolina was appointed General Counsel in 2020.


Karolina has been active as a Legal Counsel in the pharmaceutical industry for the past 15 years.


Prior to joining Oncopeptides, Karolina worked at Gilead Sciences, Nordic affiliates as Associate Legal Director.
Previously, Karolina has worked at Biovitrum and Swedish Orphan Biovitrum (Sobi) in various positions in Legal Affairs.


Karolina holds a law degree from Stockholm University.


Born: 1979
Holdings in Oncopeptides: 14,106 options**.
Other Current Positions: Board member of Oncopeptides Incentive AB.

Klaas Bakker

Klaas Bakker, MD, PhD

EVP and Chief Medical Officer, CMO

Klaas Bakker was appointed as Chief Medical Officer in 2019 and is responsible for Clinical Development Strategy, Pharmacovigilance/Patient Safety, Medical Affairs and Regulatory Affairs.


Klaas has previously held roles with increasing seniority at AstraZeneca, most recently as Vice President Medical Affairs of the Global TAGRISSO/TDR Franchise in Oncology. In this role he was responsible for the global launch of osimertinib, the company´s largest asset across all therapeutic areas.


Klaas holds an MD and is a board-certified neurosurgeon from the university of Groningen, the Netherlands, where he was clinically active until 2015. In addition, he holds a PhD in Hematology and has authored over 40 publications in international peer-reviewed journals.


Born: 1982
Holdings in Oncopeptides: 16,500 shares and 136,815 options**.

Mohamed Ladha

Mohamed Ladha

General Manager, US Business Unit

Mohamed Ladha was appointed General Manager, US Business Unit in September 2020 and leads the day-to-day operations and commercialization of the Oncopeptides Oncology portfolio for the US region.


Before Mohamed joined Oncopeptides he spent over 17 years extensively in the fields of oncology and specialty care including leading sales, marketing, market access, commercial operations and medical affairs teams at pharmaceutical and biotechnology companies.


Prior to joining Oncopeptides, Mohamed served as VP and Head of Commercial & Medical Affairs at Tocagen, a cancer-selective immuno-gene therapy company. Prior to this he led the U.S. lung cancer franchise portfolio at Takeda Oncology, and oversaw the U.S. and global lung cancer franchise portfolio at ARIAD Pharmaceuticals, today part of Takeda Oncology.


Mohamed brings extensive commercial leadership and launch experience within oncology from his roles as General Manager of Biosimilars Business at Pfizer/Hospira, Global Brand/Portfolio Lead and Commercial Development at Schering-Plough/Merck.


Mohamed holds an MBA from Northwestern University's Kellogg School of Management and an MPA from Harvard University's Kennedy School of Government. He holds a BA in Biology from Amherst, Massachusetts.


Born: 1970
Holdings in Oncopeptides: 82,367 options**.

Rolf Gulliksen, Global Head of Corporate Communications

Rolf Gulliksen

Global Head of Corporate Communications

Rolf Gulliksen was appointed as Global Head of Corporate Communications in 2020. 


Rolf has an extensive background in strategic communication for the life science industry and consultancy. Previous positions include Head of Corporate Communications at Hansa Biopharma, SVP Corporate Communications Biovitrum, Corporate Affairs Director Pfizer, VP Public Affairs and Communications Pharmacia in EMEA, and External Affairs Manager at MSD. He has also headed the life science business at leading communication agencies; Hallvarsson and Halvarsson Group, Springtime, InVivo, and Edelman Worldwide in Europe


Rolf has studied chemistry, biology, physics, geology, pedagogy and methodology at Uppsala University


Born: 1959
Holdings in Oncopeptides: 5,499 options**.
Other current positions: CEO and Senior Advisor, Gulliksen Strategic Relations AB

* Each employee option entitles the holder to acquire 900 shares per option in the company.
** The options entitles to one share per option in accordance with existing terms. For more information and terms please read under Corporate Governance – Remuneration.


Holdings in Oncopeptides AB (publ) as of September 14, 2021.